Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
43 hedge funds and large institutions have $39.9M invested in Neon Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 12 closing their positions.
114% more capital invested
Capital invested by funds: $18.6M → $39.9M (+$21.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 46 → 43 (-3)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.72M |
| 2 |
AC
Athanor Capital
New York
|
+$898K |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
+$625K |
| 4 |
MGIA
Moneta Group Investment Advisors
St Louis,
Missouri
|
+$168K |
| 5 |
State Street
Boston,
Massachusetts
|
+$99.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.8M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$319K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$295K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$222K |
| 5 |
Millennium Management
New York
|
-$197K |
NTGN Hedge Fund Activity: Q1 2020 in Review
43 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q1 2020, worth a combined $39.9M — up 114% from $18.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NTGN and 9 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.72M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.8M sold.
- 43 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q1 2020, down from 46 in Q4 2019.
- Funds reported $39.9M of Neon Therapeutics, Inc. Common Stock stock for Q1 2020, up 114% quarter-over-quarter.
- 9 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q1 2020 and 12 closed out, a net change of -3 holders.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q1 2020 was Armistice Capital, an estimated $1.72M added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q1 2020 was Fidelity Investments, an estimated $1.8M sold.
Based on aggregated 13F filings for Q1 2020.